Virax Biolabs CEO Touts Nasdaq Compliance, Cash Runway, and Fosun Deal in Letter to Shareholders
VRAX sits 64% above its 52-week low of $2.5 on light trading volume (0.1× avg).
Summary
Virax Biolabs' CEO updated shareholders on Nasdaq compliance, a $6.4M cash balance, and a Fosun Diagnostics supply deal, while flagging that the stock trades below its cash and book value.
Key Events · Corporate Governance and Compliance · VRAX
-
Nasdaq Compliance Regained
On July 13, 2026, Nasdaq confirmed that Virax had regained compliance with the minimum bid price requirement following its 1-for-25 reverse stock split, removing delisting risk.
-
Strong Cash Position
As of March 31, 2026, the company reported $6.4M in cash against only $1.0M in total liabilities, with an additional $3.3M raised from warrant exercises post-fiscal year end.
-
Fosun Diagnostics Supply Agreement
A multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets was announced, supporting near-term revenue potential.
-
Management Highlights Valuation Disconnect
CEO James Foster noted that the public market valuation remains below the company's audited cash balance and shareholders' equity, suggesting the market is undervaluing its assets and progress.
Analysis · VRAX · Life Sciences
The CEO's shareholder letter pulls together several encouraging developments: Nasdaq compliance restored after the reverse split, a fortified cash position of $6.4M plus $3.3M from warrant exercises, and a commercial supply agreement with Fosun Diagnostics. Management goes further, stating outright that the market valuation sits below cash and equity—a clear signal of disconnect. For a micro-cap biotech carrying a going concern warning, this update tackles survival and execution risks head-on, making it a notable positive.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRAX was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $2.50 to $28.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.